Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06573424
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-15
Brief Title:
TirellizumabAnlotinib VS Anlotinib for MSS-type CRC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy AND Multiomic Molecular Characterization of Tirellizumab Combined With Anlotinib in in MSSpMMR Metastatic Colorectal Cancer Data From a Retrospective Multicenter Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer To investigate the effective biomarker of anlotinib combined with tiralizumab
Detailed Description:
This was a multicenter retrospective cohort study to compare the efficacy of tyrosine kinase inhibitorTKI combined with immune checkpoint inhibitorsICIs versus tyrosine kinase inhibitor alone in the treatment of advanced MSS colorectal cancer Patients with MSS CRC who have been confirmed by pathology and have relapsed or failed multiline therapy were included in the study Patients who had received tirellizumab plus anlotinib were considered the combination group and those treated with anlotinib were classified as the monotherapy group The efficacy and safety of the two regimens were compared At the same time Whole-exome sequencing and transcriptome sequencing were performed on the patients in the response and non-response groups of the combination group to reveal the characteristics of their microenvironment and search for biomarkers related to response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None